WIXLIB

OUR RESEARCH SITESAbbVie Stemcentrx LLC –South San Francisco, California240 EmployeesAbbVie Stemcentrx LLC leverages proprietaryplatforms to identify and functionallycharacterize cancer stem cells (CSCs), whichare the sub-population of cancer cells that leadto tumor growth and metastases. This focusenables the discovery of novel CSC-associatedoncology targets.Stemcentrx scientists are experts in usingthese leads to develop clinical candidateantibody-drug conjugates (ADCs) directed toCSC. Their expertise in protein engineering,preclinical validation in patient derivedxenograft models, and in ADC manufacturingand development allows for accelerateddevelopment of first-in-class therapeutics.AbbVie – Redwood City, California215 EmployeesAbbVie Redwood City is a state of the art R&Dcenter for AbbVie, located in the San FranciscoBay Area that is focused on the discovery anddevelopment of novel cancer therapies. Keyareas of specialization include ImmunoOncology Research and Development, proteinengineering and translational biomarkers.AbbVie’s oncology experts at this site arepassionate about applying their cross-functionalexpertise in the areas of discovery biology, proteinengineering, biologics manufacturing, pre-clinicaldevelopment, translational sciences and clinicaldevelopment to bring breakthrough cancertreatments to patients. Some of the productsdiscovered and developed at this site that arecurrently on the market include: Empliciti (elotuzumab; in collaboration with BMS for thetreatment of multiple myeloma). Also, in the lastfour years, our teams have created a promisingpipeline of oncology treatments that includesseven clinical programs: Teliso-V (cMET-ADC),ABT-165 (DLL4xVEGF mAb), ABBV-085(LRRC15-ADC), ABBV-428 (I-O mAb), ABBV927 (I-O mAb), ABBV-368 (I-O mAb), and ABBV181(I-O mAb), and multiple I-O pre-clinical anddiscovery programs. Furthermore, in additionto the scientific expertise that resides at AbbVieRedwood City, key business functions such asGlobal Commercial Development, BusinessDevelopment and AbbVie Ventures are alsobased at this site.The Stemcentrx pipeline includesrovalpituzumab tesirine (Rova-T), an ADCin Ph3 for the treatment of DLL3-positiveneuroendocrine tumors , five early phaseclinical programs across various solid tumorindications, and many more biologics in earlierstages of research and development.AbbVie Stemcentrx has state-of-the-artdiscovery, preclinical research and clinicalmanufacturing and development capabilitiescollocated under one roof in the heart of theAbbVie West Coast biotech hub, in SouthSan Francisco, CA.Back to Homeabbvie.com/onc-jobs 11

WHAT IT TAKES TO OUTSMART CANCER12 abbvie.com/onc-jobsBack to Home

WHAT IT TAKES TO OUTSMART CANCERFrom Human Genome to Human BenefitFirst, he helped map the human genome. Now he’s taking that knowledge one step further. Watch how scientist Tom Hudsonand his team are working to find real-world applications for the human genome in the field of oncology.Watch Video“Great science takes great talent. By investing in groundbreakingscience, technology and—most importantly—dedicatedresearchers, AbbVie generates the insights necessary to delivera new wave of oncology treatments. I’m proud of the importantwork our teams are doing every day to help better the lives ofpeople living with cancer and their loved ones.”– Thomas Hudson M.D., Vice President, Oncology Discovery and Early DevelopmentBack to Homeabbvie.com/onc-jobs 13

WHAT IT TAKES TO OUTSMART CANCERTo make a remarkable impact on the lives of people withcancer, we are focused on delivering transformative therapiesaddressing the unmet needs in a selected set of debilitating andwidespread cancers.System BiologySystem biology is computational modeling of multidimensionalbiological systems that cannot be explained according to directone-to-one interactions. We apply system biology to inductivebottom up observation of human phenomena to generate andtest hypotheses that prioritize clinical relevance and impactof a given research project. In immuno-oncology, we utilizethis strategy to identify the cause for the resistance of cancerto immunotherapy. The latter is a multifactorial phenomenonthat does not follow a linear cause/effect process but rather achaotic mix of determinants that can only be dissected throughnonlinear pattern recognition similar to the way the weatherforecast is assembled.14 abbvie.com/onc-jobsBack to Home

WHAT IT TAKES TO OUTSMART CANCERAbbVie’s Primary Disease Focus in OncologyHematology Chronic Lymphocytic Leukemia (CLL) Non-Hodgkin’s Lymphoma (NHL) Acute Myeloid Leukemia (AML)Solid Tumors Lung Cancer– Non-Small Cell Lung Cancer (NSCLC)– Small Cell Lung Cancer (SCLC) Breast Cancer Colorectal Cancer (CRC) Glioblastoma (GBM)Back to Homeabbvie.com/onc-jobs 15

INNOVATION TAKES PERSEVERANCE & KNOWLEDGECommercial InnovationBuilding on our market leadership, we continue to bring our promotedproducts to patients around the world. Our strong track record ofexecution is key to our success.Developing MarketsOur research is committed to discovering and developing targetedtherapies that work against the processes cancer cells need to survive.We are investigating both small and large molecule approaches, andour internal research efforts are balanced with external collaborationsacross industry, academia and health care authorities.Product LaunchesWe develop advanced medicines that demonstrate both strong clinicalperformance and strong economic value. Agility and smart decisionmaking help drive our teams to be first to market.AbbVie Products ListCore Set of BiologiesApoptosis: Some cancer therapies, like BCL-2 inhibitors, can helpinduce apoptosis, or programmed cell death, an essential naturalprocess that eliminates damaged, unneeded or dangerous cells fromthe body. Dysregulation of apoptosis by cancer cells contributes to thedevelopment and progression of cancer and can lead to resistance tocancer treatments.Targeted Cell Signaling: Interfering with the communication signalsof malignant cells within tumors can be an effective way to fight cancer.BTK inhibitors block the activity of Bruton’s tyrosine kinase (BTK),which is a protein involved in the communication of signals within Bcells.DNA Damage: Cancer cells are typically hobbled with respect toDNA repair and are therefore more sensitive to DNA damage thanare normal cells. Rational and targeted DNA-repair modulators, likePARP inhibitors, can be an effective way to fight cancer given thegrowing evidence from the early development of multiple DNA repairmodulators.16 abbvie.com/onc-jobsCancer Stem Cells: Cancer stem cells fuel tumor growth and spreadthroughout the body; understanding the biology of these cancer stemcells will guide us in developing therapies specifically targeted todestroy them.Immuno-Oncology (I-O): I-O therapies are bringing durable andremarkable benefits to patients by utilizing the body’s immune systemto help fight cancer. We believe there are many promising I-O targets(e.g., CD40, OX40) and ways of optimizing the immune response thatremain to be discovered, explored and developed.Epigenetics: Epigenetic abnormalities are frequent events implicatedin the development of many types of cancer. Drugs that modulateepigenetic proteins and the architecture of DNA can influence multiplegenes critical to the progression of human tumors.Cutting-Edge TechnologiesADCs/Empowered Biologics: Our expertise in biologics and chemistryallows us to discover and develop novel molecules that deliver highlytoxic drugs directly to cancer cells, allowing more effective killing ofcancer cells while minimizing side effects, thus leading to more effectiveand safer cancer drugs.DVD/Bipecifics: Our strength in protein engineering allows us todevelop multi-specific molecules that attack the cancer from multipleangles at the same time; creating a response that is stronger than thetwo drugs administered simultaneously. Furthermore, it allows us tocreate molecules that have unique biological activities and benefitsthat rise from the simultaneous binding of both targets.Small Molecules: Our expertise in chemistry allows us to designmolecules that range from enzyme inhibitors to molecules that blockthe interactions of critical proteins. Furthermore, small molecules canbe orally administered without the need to go to the hospital, therebyempowering the patient.T-Cell Receptors: T-cell receptors can recognize aberrant peptidesdisplayed on tumor cells. Our expertise in the engineering of humanforms of T-cell receptors allows us to discover and develop nextgeneration cancer biologics that target tumor cells with toxic drugs orto direct immune cells to kill cancer cells.Back to Home

PARTNERSHIPSACCELERATING LEARNING. BUILDING CAPABILITIES.We believe that the best way to achieve our goal of having a remarkable impact on the lives of people affected by canceris to combine our dedicated and experienced team with innovative partnerships and collaborations that foster sharingof knowledge to deliver access to the best care for patients. We collaborate with research and academic institutions todeepen our knowledge of the core areas of biology with the goal to develop accelerated breakthroughs for cancer patients.We partner with other companies who share our commitment to oncology to strengthen our pipeline and advance thetechnologies aimed at striving to provide better medicines for patients.Collaboration also allows us to work with patient associations, physician associations, payors, government and otherstakeholders to explore and identify ways to provide patients with access to the best care.We continue to look for innovative partners that complement our strengths, capabilities and commitment.Corporate PartnersAcademic and Medical Center PartnersBack to Homeabbvie.com/onc-jobs 17

A POWERFUL PIPELINEAbbVie has a deep heritage in oncology research, and the technology and approaches we are taking to advance cancertreatment are becoming foundational to the next generation of cancer treatment. Our efforts combine core areas of biologywith cutting-edge technologies to deliver smarter solutions faster to the oncology community.As our pipeline grows, so does our opportunity to commercialize our products. Here is a select list of our commercializedproducts and a link to our active clinical trials.Marketed ProductsMechanism of ActionWe know someone is waiting; that’s why we do everything in our powerto bring life-changing medicine to market the most efficient and safeway. Our products are approved in individual countries for specificuses, and the information provided is governed by local regulations. Wehave more than 30 products in the market.The BCL-2 gene prevents apoptosis of some cells, includinglymphocytes, and can be over expressed in CLL cells. Venetoclax isdesigned to block the function of the BCL-2 protein, which helps restorethe cell’s ability to undergo apoptosis.Development & Ongoing Clinical TrialsThese agents have the potential to transform the treatment of CLL,MCL and Waldenström’s macroglobulinemia.We continue to make very good progress with venetoclax and areevaluating regulatory timelines for other indications. Monotherapy Combination with existing therapies Novel/novel combinationsVENCLYXTO (venetoclax) Approved by European Commission in December 2016 for thetreatment of chronic lymphocytic leukemiaVENCLEXTA (venetoclax) Approved by the FDA on April 2016 under accelerated approvalconditions for the treatment of chronic lymphocytic leukemia Venetoclax is being developed by AbbVie and Roche. It is jointlycommercialized by AbbVie and Genentech, a member of the RocheGroup, in the U.S. and by AbbVie outside of the U.S.On April 12, 2016, under accelerated approval conditions, the U.S. Foodand Drug Administration approved venetoclax tablets, the first BCL-2inhibitor in relapsed/refractory chronic lymphocytic leukemia patientswith 17p deletion who have received at least one prior treatment. Thisdrug is co-developed by AbbVie, Inc. and Genentech USA, Inc.VENCLEXTA (venetoclax) is an oral selective inhibitor of B-celllymphoma-2 (BCL-2). VENCLEXTA was approved in April 2016 bythe United States Food and Drug Administration for the treatment ofpatients with chronic lymphocytic leukemia (CLL) with 17p deletion,as detected by an FDA-approved test, who have received at least oneprior therapy.18 abbvie.com/onc-jobsEMPLICITI (elotuzumab ) Approved by the FDA on November 2015 for the treatment ofmultiple myeloma Approved by the European Commission on May 2016 for thetreatment of multiple myeloma under accelerated approval conditions Bristol-Myers Squibb and AbbVie are co-developing Empliciti, withBristol-Myers Squibb solely responsible for commercial activitiesThe U.S. Food and Drug Administration has approved elotuzumab incombination with lenalidomide and dexamethasone for the treatmentof patients with multiple myeloma who have received one to three priortherapies. This drug is co-developed by AbbVie, Inc. and Bristol-MyersSquibb.EMPLICITI (elotuzumab) is a humanized monoclonal antibodydirected against SLAMF7. EMPLICITI was approved by the U.S. Foodand Drug Administration in 2015 for the treatment of multiple myelomain combination with the medicines REVLIMID (lenalidomide) anddexamethasone in people who have received one to three priortreatments for their multiple myeloma.Back to Home

A POWERFUL PIPELINEMechanism of ActionElotuzumab is a humanized monoclonal antibody directed againstSLAMF7, a cell-surface glycoprotein that is highly and uniformlyexpressed on multiple myeloma cells but is minimally expressed onnormal cells.Development & Ongoing Clinical TrialsAbbVie and Bristol-Myers Squibb jointly developed elotuzumab. Inaddition to the approved indication, AbbVie and BMS have ongoingclinical trials to assess elotuzumab in multiple myeloma.IMBRUVICA (ibrutinib) Approved by the FDA in November 2013 for mantle cell lymphoma Approved by the FDA in February 2014 for chronic lymphocyticleukemia The FDA expanded the approved use in January 2015 forWaldenström’s macroglobulinemia Approved by the FDA in March 2016 for first-line treatment of chroniclymphocytic leukemia The FDA expanded the approved use in May 2016 for smalllymphocytic lymphoma Approved by the FDA in January 2017 as a first treatment for marginalzone lymphoma Approved by the FDA in August 2017 for adult patients with ChronicGraft-Versus-Host-Disease Imbruvica is commercialized and developed by Janssen Biotech, Inc.,and Pharmacyclics, a wholly owned subsidary of AbbViePharmacyclics LLC, a wholly owned subsidiary of AbbVie, togetherwith Janssen Biotech, Inc., developed and commercialize IMBRUVICA (ibrutinib), a first-in-class, oral, once-daily medication that inhibits aprotein called Bruton's tyrosine kinase (BTK). BTK is a key signalingmolecule in the B-cell receptor that plays an important role in the survivaland spread of malignant B cells. IMBRUVICA blocks signals that tellmalignant B cells to multiply and spread uncontrollably.IMBRUVICA has eight U.S. Food and Drug Administration approvalsacross six disease indications. IMBRUVICA has also been granted fourBreakthrough Therapy Designations (BTD) by the FDA, more than anyother medication to date. BTDs are granted on a special basis by the FDAfor medical conditions that have limited treatment options and where theimmediate need for safe and effective therapies is great.We are committed to fully exploring the potential of ibrutinib and itsunique mechanism of action (MOA) across hematological oncology andother disease states.Back to Homeabbvie.com/onc-jobs 19

A POWERFUL PIPELINELate-Stage Investigational CompoundsEarly-Stage Investigational CompoundsVeliparibABT-621Veliparib is an investigational oral poly (adenosine diphosphate [ADP]ribose) polymerase (PARP) inhibitor AbbVie is evaluating in multipletumor types.ABT-621 is a first-in-class, second generation TRAIL-receptor agonistunder development for the treatment of solid and hematologic tumors.ABT-414ABT-165 is an investigational Dual Variable Domain Immunoglobulin(DVD-Ig ) that inhibits VEGF (vascular endothelial growth factor)and DLL4 (delta like ligand 4), which can potentially suppress tumorangiogenesis and tumor initiating cells. ABT-165 is being studied inPhase 1 trials. ABT-165 is in clinical trials for the treatment of patientswith advanced solid tumors.ABT-414 is an investigational EGFR (epidermal growth factor receptor)targeted monoclonal antibody drug conjugate being studied ingliobastoma.ROVA-TRova-T (rovalpituzumab tesirine) is an investigational antibody drugconjugate targeting the cancer stem cell-associated target delta-likeprotein 3 (DLL3). It is also being investigated as a combination therapywith Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo Yervoy(ipilimumab) regimen as a second-line treatment for extensive-stagesmall cell lung cancer (SCLC).ABT-165Telisotuzumab Vedotin (ABBV-399)ABBV-399 is an investigational antibody drug conjugate (ADC)targeting cMet that is being studied in a Phase 1 clinical trial in patientswith solid tumors.AbbVie’s Full Pipeline20 abbvie.com/onc-jobsBack to HomeAbbVie Marketed Products

A MEANINGFUL CAREERExplore Career Opportunitieswww.abbvieoncology.comExplore Career OpportunitiesWe are scientists, researchers, sales professionals, marketers, communicators, manufacturing specialists and regulatoryexperts, but we are also parents, brothers, sisters, friends, community leaders, volunteers and more. We have a lot incommon with the people we serve, and we come together every day with a unified passion to create, discover anddeliver new ways to help improve people’s health and address areas of unmet need in oncology.Visit www.abbvieoncology.com for more information.Back to Homeabbvie.com/onc-jobs 21

“Working at AbbVie means being committed to the patient and being dedicated to excellence. If you want towork at a place that really does give you the chance to make a meaningful impact on cancer patients, then thisis the place. Our strong oncology pipeline and commitment of R&D dollars specific to oncology is incrediblyexciting to our ability to continue to impact cancer patients for many years to come.”– William Vollmer, MPH, Oncology Sales DirectorAbbVie1 North Waukegan RoadNorth Chicago, IL 60064 U.S.A.abbvie.com180047Copyright 2018 AbbVie. All rights reserved.All numbers and data current as of October 2017Back to HomeFollow us:

portfolio in multiple indications for blood cancer, broadened the pipeline and established AbbVie as an emerging leader in the hematological oncology space. Stemcentrx (acquired 2016) Stemcentrx, now part of AbbVie, is the world leader in identifying novel cancer stem cell targets and desi